| Pharmaceutical Information |
| Drug Name |
Tafamidis |
| Drug ID |
BADD_D02107 |
| Description |
Tafamidis and tafamidis meglumine (FX-1006A) are benzoxazole derivatives[A27206] developed by FoldRX.[A189717] Tafamidis is structurally similar to diflusinal.[A189717]
Tafamidis was granted an EMA market authorisation on 16 November 2011[L6247] and FDA approval on 3 May 2019.[L11280] |
| Indications and Usage |
|
| Marketing Status |
Not Available |
| ATC Code |
N07XX08 |
| DrugBank ID |
DB11644
|
| KEGG ID |
D09673
|
| MeSH ID |
C547076
|
| PubChem ID |
11001318
|
| TTD Drug ID |
D04DFR
|
| NDC Product Code |
11014-0390; 60715-4344; 58159-079; 69988-0039; 11014-0406; 0069-8730; 60715-0647; 14501-0102 |
| Synonyms |
tafamidis | Vyndamax | Vyndaqel | FX 1006A | FX1006A | FX-1006A | tafamidis meglumine |
|
| Chemical Information |
| Molecular Formula |
C14H7Cl2NO3 |
| CAS Registry Number |
594839-88-0 |
| SMILES |
C1=CC2=C(C=C1C(=O)O)OC(=N2)C3=CC(=CC(=C3)Cl)Cl |
| Chemical Structure |
|
|
| ADR Related Proteins Induced by Drug |
| ADR Term |
Protein Name |
UniProt AC |
TTD Target ID |
PMID |
| Not Available | Not Available | Not Available | Not Available | Not Available |
|
| ADRs Induced by Drug |
|
|
